Literature DB >> 34300309

Differential Diagnosis of Azoospermia in Men with Infertility.

Danilo L Andrade1, Marina C Viana2, Sandro C Esteves3,4.   

Abstract

The differential diagnosis between obstructive and nonobstructive azoospermia is the first step in the clinical management of azoospermic patients with infertility. It includes a detailed medical history and physical examination, semen analysis, hormonal assessment, genetic tests, and imaging studies. A testicular biopsy is reserved for the cases of doubt, mainly in patients whose history, physical examination, and endocrine analysis are inconclusive. The latter should be combined with sperm extraction for possible sperm cryopreservation. We present a detailed analysis on how to make the azoospermia differential diagnosis and discuss three clinical cases where the differential diagnosis was challenging. A coordinated effort involving reproductive urologists/andrologists, geneticists, pathologists, and embryologists will offer the best diagnostic path for men with azoospermia.

Entities:  

Keywords:  azoospermia; diagnosis; endocrine evaluation; genetic testing; male infertility; nonobstructive azoospermia; review; sperm retrieval; spermatogenic failure; testis biopsy

Year:  2021        PMID: 34300309     DOI: 10.3390/jcm10143144

Source DB:  PubMed          Journal:  J Clin Med        ISSN: 2077-0383            Impact factor:   4.241


  9 in total

1.  Unusual association between testicular tuberculosis and microdeletion of the Y chromosome in an infertile patient with azoospermia.

Authors:  Moez Rahoui; Yassine Ouanes; Kays Chaker; Mokhtar Bibi; Kheireddine Mourad Daly; Ahmed Sellami; Sami Ben Rhouma; Yassine Nouira
Journal:  Ann Med Surg (Lond)       Date:  2022-06-25

Review 2.  Evolution of the World Health Organization semen analysis manual: where are we?

Authors:  Sandro C Esteves
Journal:  Nat Rev Urol       Date:  2022-05-06       Impact factor: 16.430

3.  Recombinant gonadotropin therapy to improve spermatogenesis in nonobstructive azoospermic patients - A proof of concept study.

Authors:  Rita Jakubcionyte Laursen; Birgit Alsbjerg; Helle Olesen Elbaek; Betina Boel Povlsen; Kirsten Brock Spanggaard Jensen; Jette Lykkegaard; Sandro C Esteves; Peter Humaidan
Journal:  Int Braz J Urol       Date:  2022 May-Jun       Impact factor: 3.050

4.  Construction and external validation of a 5-gene random forest model to diagnose non-obstructive azoospermia based on the single-cell RNA sequencing of testicular tissue.

Authors:  Ranran Zhou; Xianyuan Lv; Tianle Chen; Qi Chen; Hu Tian; Cheng Yang; Wenbin Guo; Cundong Liu
Journal:  Aging (Albany NY)       Date:  2021-11-04       Impact factor: 5.682

5.  Update on the Management of Non-Obstructive Azoospermia: Current Evidence and Unmet Needs.

Authors:  Ettore Caroppo; Giovanni M Colpi
Journal:  J Clin Med       Date:  2021-12-23       Impact factor: 4.241

6.  Membrane Transporters and Carriers in Human Seminal Vesicles.

Authors:  Damian Malinowski; Paweł Grzegółkowski; Katarzyna Piotrowska; Marcin Słojewski; Marek Droździk
Journal:  J Clin Med       Date:  2022-04-15       Impact factor: 4.964

7.  Association study of novel single nucleotide polymorphisms of androgen receptor and estrogen receptor-α genes with male infertility in Northwest of Iran: A case-control study.

Authors:  Elham Ghadirkhomi; Seyed Abdolhamid Angaji; Maryam Khosravi; Mohammad Reza Mashayekhi
Journal:  Int J Reprod Biomed       Date:  2022-07-06

8.  Expression of G-Protein-Coupled Estrogen Receptor (GPER) in Whole Testicular Tissue and Laser-Capture Microdissected Testicular Compartments of Men with Normal and Aberrant Spermatogenesis.

Authors:  Renata Walczak-Jędrzejowska; Ewa Forma; Elżbieta Oszukowska; Magdalena Bryś; Katarzyna Marchlewska; Krzysztof Kula; Jolanta Słowikowska-Hilczer
Journal:  Biology (Basel)       Date:  2022-02-26

9.  Microdissection TESE versus conventional TESE for men with nonobstructive azoospermia undergoing sperm retrieval.

Authors:  Sandro C Esteves
Journal:  Int Braz J Urol       Date:  2022 May-Jun       Impact factor: 3.050

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.